Arcellx, Inc. (ACLX) 8-K Current Report: February 23, 2026
Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)Arcellx, Inc. (ACLX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 7.01: Regulation FD Disclosure
Arcellx, Inc. 8-K Feb 23, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Gilead Sciences acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, totaling up to $120.00/share
- • CVR pays $5.00 only if anito-cel cumulative worldwide sales exceed $6.0B by December 31, 2029 — milestone is high-bar, payment not guaranteed
- • Two-step deal: tender offer (min 20 business days) followed by Section 251(h) back-end merger — no shareholder vote required
- • Termination fee of $260M payable by Arcellx to Gilead if deal breaks under specified circumstances, limiting competing bid scenarios
- • Support stockholders owning ~10.3% of shares already committed to tender, providing early deal momentum
Item 7.01 · Regulation FD Disclosure
- • Arcellx merger agreement announced Feb 23, 2026 alongside FDA acceptance of BLA for anito-cel
- • Anito-cel targets BCMA for relapsed/refractory multiple myeloma — BLA acceptance signals regulatory review underway
- • Dual catalyst event: M&A transaction + FDA milestone disclosed simultaneously, high strategic significance for shareholders
Get deeper insights on Arcellx, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.